Barclays raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $467 from $435 and keeps an Equal Weight rating on the shares. The ...
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $459 from $450 and keeps an Equal ...
Conestoga Capital Advisors, an asset management company, released its fourth-quarter 2024 investor letter. A copy of the ...
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for.
New! Sign up for our free email newsletter.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback